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Introduction: Autologous mesenchymal stem cells (MSCs) are an attractive concept in regenerative medicine, but
their mechanism of action remains poorly defined. No immune response is reported after in vivo injection of
allogeneic equine MSCs or embryo-derived stem cells (ESCs) into the equine tendon, which may be due to the
cells’ immune-privileged properties. This study further investigates these properties to determine their potential for
clinical application in other tissues.
Methods: Mitomycin C-treated MSCs, ESCs, or differentiated ESCs (dESCs) were cultured with allogeneic equine
peripheral blood mononuclear cells (PBMCs), and their effect on PBMC proliferation, in the presence or absence of
interferon-gamma (IFN-γ) was determined. MSCs and super-antigen (sAg)-stimulated PBMCs were co-cultured
directly or indirectly in transwells, and PBMC proliferation examined. Media from MSC culture were harvested and
used for PBMC culture; subsequent PBMC proliferation and gene expression were evaluated and media assayed for
IFN-γ, tumor necrosis factor alpha (TNF-α), and interleukin (IL)-10 and IL-6 proteins with enzyme-linked immunosorbent
assay (ELISA).
Results: Co-culture of PBMCs with ESCs or dESCs did not affect baseline proliferation, whereas co-culture with
MSCs significantly suppressed baseline proliferation. Stimulation of PBMC proliferation by using super-antigens
(sAgs) was also suppressed by co-culture with MSCs. Inhibition was greatest with direct contact, but significant
inhibition was produced in transwell culture and by using MSC-conditioned media, suggesting that soluble factors
play a role in MSC-mediated immune suppression. The MSCs constitutively secrete IL-6, even in the absence of
co-culture with PBMCs. MSC-conditioned media also brought about a change in the cytokine-expression profile of
sAg-stimulated PBMCs, significantly reducing PBMC expression of IL-6, IFN-γ, and TNF-α.
Conclusions: Equine MSCs and ESCs possess a degree of innate immune privilege, and MSCs secrete soluble
factors that suppress PBMC proliferation and alter cytokine expression. These properties may make possible
the future clinical use of allogeneic stem cells to help standardize and broaden the scope of treatment of
tissue injuries.Introduction
The use of autologous mesenchymal stromal/stem cells
(MSCs) in clinical practice to aid tendon regeneration in
horses [1] has gained popularity and acceptance in the
last decade. Results from the clinical and experimental
use of MSCs in regenerative medicine [2-5] have been
promising, but details of the cellular mechanism of ac-
tion remain unknown. Previous work has shown that* Correspondence: debbie.guest@aht.org.uk
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low (39% retention 6 hours after intra-arterial regional
limb perfusion, 28% retention after intravenous adminis-
tration [6,7], and <5% survival 10 days after implantation
[8]), which suggests that their beneficial effects are not
brought about solely through their direct differentiation
into tendon cells.
This theory is supported by the results of other studies
using MSCs, which have shown them to function through
trophic effects on endogenous cells [9] rather than
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in vivo [10] and in vitro [5,11], and these attributes
may render them potential candidates for the treat-
ment of inflammatory conditions.
MSCs are currently being used in human trials to re-
duce inflammation in a range of conditions such as
spinal cord injury [12], knee osteoarthritis [13], and liver
failure [14]. In horses, immunomodulatory properties
may suggest that equine MSCs could have potential use
in the future treatment of inflammatory conditions such
as osteoarthritis [15] or inflammatory airway disease.
Current clinical practice uses autologous MSCs. How-
ever, this approach requires aspiration of bone marrow
from every horse, an invasive technique with the risk of
potential complications, such as pneumopericardium
[16]. After aspiration, culture expansion of MSCs to ob-
tain sufficient numbers for clinical use can take up to
4 weeks, precluding the treatment of acute injuries dur-
ing the initial inflammatory peak. In addition, treatment
of each individual by using MSCs obtained from that in-
dividual makes it impossible to standardize treatment
fully. In the horse, embryo-derived stem cells (ESCs)
[17,18] are also being investigated for their potential to
aid tendon regeneration [8,19] by providing an allogen-
eic source of cells that could be standardized to provide
an “off-the-shelf” treatment. Equine ESCs have a high
survival in the injured horse tendon without inducing
any apparent immune response [8]. Furthermore, they
appear to undergo some degree of tenocyte differenti-
ation, which has also been demonstrated in vitro in re-
sponse to TGF-β3 and 3D culture [20]. However,
whether equine ESCs would be immune privileged after
transplantation and differentiation into other tissues re-
mains unknown.
Many of the limitations of current autologous treat-
ment could be overcome by the use of allogeneic MSCs
or ESCs. Work in other species has demonstrated that
ESCs are immune privileged to some degree, although
they may ultimately still be recognized and consequently
rejected by the immune system [21-24]. Likewise, both
human and equine MSCs possess some ability to modu-
late an immune response [25-29], although their precise
mechanism of action is largely unknown. It was previ-
ously shown that allogeneic equine MSCs can be trans-
planted into the injured tendon (single dose) [8],
injected intradermally (two doses, 3 to 4 weeks apart)
[30] or intraarticularly (single dose) [31] without eliciting
an apparent immune response. Additionally, no changes
in cellular or humoral immunity parameters were re-
ported after intravenous injection of allogeneic MSCs
into six healthy horses [32]. Recent in vitro results
showed that equine MSCs do not significantly alter the
baseline proliferation of nonactivated T cells [28,30], but
that they can decrease the proliferation of stimulated Tcells [28]. When in co-culture with stimulated T cells,
the MSCs were found to produce increased amounts of
prostaglandin and IL-6 and to decrease the production
of TNF-α and IFN-γ by the T cells. Secreted prostaglan-
din E2 recently was shown to be involved in equine
MSC-mediated T-cell suppression [29].
To determine whether equine ESCs have the potential
to be used in the treatment of injuries to tissue other
than tendon, where cell replacement may be beneficial,
we determined whether they were immune privileged
in vitro by performing co-cultures with equine periph-
eral blood mononuclear cells (PBMCs). We also deter-
mined whether equine MSCs had immune-modulatory
properties and if this was dependent on direct cell-to-
cell contact. In addition, we examined the resulting
cytokine-expression profile of PBMCs after culture in
MSC-conditioned media.
Methods
All of the work described was performed with the ap-
proval of the Animal Health Trust Ethical Review Com-
mittee and, where live experimental animals were
involved, under UK Home Office Licence.
Stem cell culture
Three lines of previously characterized ESCs [17,18]
were used in this study. ESCs were cultured on mitoti-
cally inactivated mouse embryonic fibroblasts at 37.5°C,
5% CO2, in ESC medium (DMEM/F12 containing 15%
fetal bovine serum, 2 mM L-glutamine, 1% nonessential
amino acids, 1 mM sodium pyruvate, 0.1 mM 2-
mercaptoethanol (all from Invitrogen, Renfrewshire,
UK), and 1,000 units/ml leukemia inhibitory factor (LIF)
(Sigma, Dorset, UK)). ESCs were passaged mechanically
every 5 to 7 days in the presence of Effectine (PAA La-
boratories, Somerset, UK). To induce differentiation,
ESCs were passaged into conditions without feeder cells
in the absence of LIF.
MSCs were derived from bone marrow aspirates taken
from live Thoroughbred geldings, as described previ-
ously [33] or from Welsh mountain ponies immediately
after euthanasia for reasons unrelated to this study. All
MSCs were characterized according to their expression
of surface antigens and tri-lineage differentiation, as de-
scribed previously [34]. Two 10.5-ml aliquots of bone
marrow were aspirated into heparin (Sigma). Bone mar-
row was centrifuged through histopaque (Sigma), and
the buffy layer of mononuclear cells was collected and
washed in culture medium (DMEM supplemented with
10% fetal calf serum, 2 mM L-glutamine, 100 U/ml peni-
cillin, and 100 μg/ml streptomycin (all from Invitrogen,
Paisley, UK)) before plating all recovered cells in 10 ml
medium onto a 10-cm plate for incubation at 37.5°C, 5%
CO2. Medium was replaced every 2 to 3 days to remove
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0.25% trypsin-EDTA (Sigma) every 3 to 7 days and replated
at a seeding density of approximately 10,000 cells/cm2.
Cells at passages 2 to 4 were frozen in liquid nitrogen until
needed for culture.
Equine MSCs and ESCs were plated in standard growth
media and allowed to attach overnight before the addition
of 100 ng/ml equine IFN-γ (R&D Systems, Abingdon,
UK) for 72 h.
Peripheral blood mononuclear cell isolation, culture, and
stimulation with mitogen or Streptococcus equi
superantigens
Peripheral blood mononuclear cells (PBMCs) were puri-
fied by centrifugation on Ficoll-Hypaque (Amersham
Biosciences, Uppsala, Sweden), as previously described
[35]. Blood was collected from Welsh mountain ponies
(not the same ponies from which MSCs were obtained)
for reasons unrelated to this study, and only excess
PBMCs were used for the following experiments. Pellets
of excess PBMCs were resuspended in 1 ml of PBMC
media (RPMI-1630 (Sigma) with 10% heat-inactivated
fetal calf serum, 100 U/ml penicillin, and 100 μg/ml strepto-
mycin, 2 mM L-glutamine, and 55 μM 2β-mercaptoethanol
(as before)) and numerated.
For culture-stimulation experiments, PBMCs were
treated with phytohemagglutinin (PHA) (Sigma) at a
concentration of 5 μg/ml or Streptococcus equi super-
antigens (sAgs) (SeeM, SeeL, SeeI, and SeeH, each at a
final concentration of 0.125 μg/ml (AHT Bacteriology
Unit)), as previously described [36].
Mixed lymphocyte reactions and co-cultures
For MLRs, mitomycin C (MMC)-treated MSCs and dif-
ferentiated ESCs (125 μg/ml MMC for 2-hour incuba-
tion) were cultured in 96-well plates in the presence of
nonstimulated effector PBMCs at a ratio of 1:2 stem
cells/PBMCs. For the negative control, MMC-treated
PBMCs (50 μg/ml MMC for 30 minutes) were washed
and cultured with homologous effector PBMCs. For the
positive control, MMC-treated PBMCs were cultured
with heterologous effector PBMCs, both at ratios of 1:2
stimulator/effector PBMCs. After 5 days, PBMCs were
treated with radioactive thymidine (3H thymidine) (GE
Healthcare Bio-sciences) at a final concentration of 0.5 μCi
per well and incubated at 37°C, 5% CO2 for 16 to 18 hours.
Cells were harvested and numerated. Three replicates
using three lines of cells were performed.
For the ESCs co-cultures were also performed in six-
well plates because undifferentiated ESCs grow in colonies
and require monolayer culture on a feeder layer to main-
tain their undifferentiated state. Therefore MMC-treated
undifferentiated ESCs and differentiated ESCs were cul-
tured with nonstimulated effector PBMCs at various ratiosranging from 1:25 to 1:100 in six-well plates. After 5 days,
the proliferation of the PBMCs was determined by using
3H-thymidine incorporation. Six replicates with three lines
of ESCs were performed.
To determine the immune modulatory properties of
MSCs, MMC-treated MSCs were co-cultured with allo-
geneic PHA or sAg-stimulated PBMCs in six-well plates at
ratios of 1:10 to 1:400. After 3 days, PBMC numbers were
determined by using 3H-thymidine incorporation, and a
percentage inhibition value for proliferation was calculated
by using the formula: 100-((condition-NAx100)/(sAg-NA))
(where NA is nonactivated PBMCs, and sAg is sAg-
stimulated PBMCs). Three replicates using MSCs isolated
from three different horses were performed.
Transwell cultures
Six-well plate transwell cultures with a 0.4 μM mem-
brane pore size (Corning, Costar, Cambridge, MA, USA)
were used to separate the MSCs physically from the
sAg-stimulated PBMCs. PBMCs at a concentration of
10 × 106 cells/ml were stimulated with sAg, as previously
described, and co-cultured with 1 × 105 MMC-treated
MSCs, with the PBMCs in the inner chamber of the well
and the adherent MSCs in the outer chamber. After
3 days, the PBMCs were quantified by using 3H-thymi-
dine incorporation. Three replicates with MSCs isolated
from three different horses were performed.
MSC-conditioned media
MSCs were cultured on 10-cm plates until 70% to 80%
confluent. Media were removed and replaced with PBMC
medium, which was then harvested after 24, 48, and
72 hours. This supernatant, termed “MSC-conditioned
medium,” was then filtered through a 0.22-μm filter
(Nalgene, UK) and maintained at 4°C before use. sAg-
stimulated PBMCs and nonactivated PBMCs were incu-
bated for 3 days with conditioned media from each time
point. After incubation, the PBMCs were either quanti-
fied by using 3Hthymidine incorporation or centrifuged
to pellet the cells, after which the supernatant was
maintained at −20°C until use in ELISAs, and PBMCs
were resuspended in 1 ml TRIzol (Ambion, Paisley,
UK). Three replicates using MSCs isolated from three
different horses were performed.
Immunohistochemistry
MSCs or ESCs were cultured on gelatin-coated (Sigma,
Dorset, UK) coverslips with or without the addition of
100 ng/ml equine IFN-γ (R + D Systems, Abington, UK)
for 72 hours, fixed in 3% paraformaldehyde (in PBS) for
20 minutes at room temperature, and permeabilized for
1 hour with 0.1% Triton-X-100 at room temperature.
Primary antibody incubations with mouse anti-MHCI
1:200 and mouse anti-MHCII 1:200 (both VMRD,
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fore detection with a secondary antibody goat anti-mouse
FITC 1:200 (Abcam, Cambridgeshire, UK). Three repli-
cates for each cell type were performed by using cells iso-
lated from different animals.
Quantitative reverse transcription PCR
PBMC total RNA was extracted by using TRIzol reagent
followed by RNA isolation with RNeasy minicolumns
and reagents (Qiagen Ltd., Crawley, Surrey, UK). Residual
DNA was removed by performing an on-column DNAse
digestion by using an RNase-free DNAse kit (Qiagen
Ltd.), after which cDNA was synthesized by using the
Superscript First-Strand Synthesis System for RT-PCR
(Invitrogen). One-microliter aliquots of cDNA diluted
1:1,000 were amplified by polymerase chain reaction on
a Quantica qPCR instrument (Techne), by using gene-
specific primers (Table 1) in a 25-μl reaction volume
with a SYBR Green Core Kit for detection (Eurogentec,
Seraing, Belgium). Relative expression levels were nor-
malized with the housekeeping gene 18S and calculated
with the 2-ΔΔCT method [37]. Three replicates using
conditioned media from MSCs isolated from three dif-
ferent horses were performed.
ELISA assay
The IL-6, IL-10, IFN-γ, and TNF-α concentrations in
MSC-conditioned media were measured both before and
after PBMC culture, by using species-specific competi-
tive inhibition ELISAs (BlueGene, Shanghai, China, and
R&D Systems, Abingdon, UK) measured in duplicate on
a microplate absorbance reader (ThermoMax Technolo-
gies, Columbia, MD, USA). Three replicates with condi-
tioned media from MSCs isolated from three different
horses were performed.
Statistical analysis
Data were analyzed by using one-way ANOVA with post
hoc Tukey where appropriate (SPSS, IBM). Paired data
were compared by using a Student t test. A P value of <0.05
was considered significant.Table 1 Primers used for RT-PCR [38]
Primer Forward (5′-3′)
18S ATGCGGCGGCGTTATTCC
TNF-α AAAGGACATCATGAGCACTGAA
IFN-γ CTACCTATTACTGCCAGGCCG
IL-6 TGCTGGCTAAGCTGCATTCA
IL-8 TTGGCCGTCTTCCTGCTTT
IP-10 CCTCCAGTTGCAGCACCAT
CCL5 CACTGCCACCTTCTGCACTCResults
Equine ESCs do not induce the proliferation of equine
PBMCs, even after differentiation and pretreatment with
IFN-γ
IFN-γ pretreatment of ESCs qualitatively increased the
intensity of MHC I staining on both undifferentiated and
differentiated cells. However, no induction of MHC II an-
tigens was observed (Figure 1A). The proliferative re-
sponse of equine PBMCs was measured after co-culture
with either undifferentiated ESCs or ESCs that had under-
gone spontaneous differentiation for 7 days. No increase
in PBMC proliferation was observed, even after differenti-
ation (Figure 1B). MHC I upregulation by IFN-γ did not
cause ESCs (either undifferentiated or differentiated) to
produce a proliferative response from allogeneic PBMCs
(Figure 1B).
Equine bone marrow-derived MSCs suppress background
proliferation of unstimulated PBMCs even after pretreat-
ment with IFN-γ
MSCs express MHC class I antigens, but no MHC class
II antigens are detected by using immunocytochemistry.
After exposure to IFN-γ, the intensity of MHC I staining
is qualitatively increased, and MHC II expression is in-
duced (Figure 2A and [34]). When directly co-cultured
with bone marrow-derived MSCs, the baseline level of
PBMC proliferation is significantly reduced to approxi-
mately 10% of the baseline (Figure 2B; P = 0.00001). This
finding is in contrast to that observed with ESCs. Fur-
thermore, after treatment with IFN-γ, MSCs continue to
decrease significantly the baseline level of PBMC prolif-
eration (Figure 2B; P = 0.000002) to a level similar to
that of nontreated MSCs with proliferation-inhibition
values of 82.5% and 87.7%, respectively.
Equine bone marrow-derived MSCs suppress PBMCs
activated with either PHA or sAgs
Phytohemagglutinin (PHA) is commonly used to stimu-
late PBMC proliferation [39]. We previously demonstrated
that streptococcal sAgs can also lead to PBMC prolifera-
tion [36]. By using either mitogen to stimulate PBMC pro-
liferation, we found that co-culture with MSCs results inReverse (5′-3′)
GCTATCAATCTGTCAACTCCT
AG GGGCCCCCTGCCTTCT
TCCAGGAAAAGAGGCCCAC
GGAAATCCTCAAGGCTTCGAA
GGTTTGGAGTGCGTCTTGATG
TTCCTTGAGTTCCACTCAGAGTCA
CGGGAGATGTAGGCAAAGCA
Figure 1 Proliferation of equine PBMCs is not induced by co-culture with equine ESCs. (A) Immunocytochemical staining of IFN-γ-treated
embryo-derived stem cells (ESCs) for MHC I and MHC II. Cell nuclei are indicated by blue Dapi staining, and expressed MHC I or II proteins, by
green staining. Representative images from one of three replicates are shown. (B) Relative proliferation of peripheral blood mononuclear cells
(PBMCs) to undifferentiated (ESCs) and differentiated (dES) ESCs cultured in the presence and absence of IFN-γ, where NA is baseline, nonactivated
PBMC proliferation; sAg is superantigen-stimulated PBMCs (positive control); IFN-γ is 72-hour pretreated undifferentiated or differentiated ESC. *Results
significantly different relative proliferation when compared with NA PBMCs (P < 0.05). Error bars represent the standard error of seven individual
experimental repeats using three different cell lines.
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cause the use of sAgs results in a greater, more consistent
induction of PBMC proliferation, sAgs were used in all
subsequent experiments.
MSCs suppress the proliferation of activated PBMCs to
equivalent levels independent of the ratio
To determine whether the suppressive effects of the
MSCs are lost with an increasing MSC-to-PBMC ratio,
MSCs were co-cultured with sAg-activated PBMCs at
ratios from 1:10 to 1:400. No significant differences were
observed in the percentage inhibition within the tested
ratio range, with inhibition remaining consistently high,
at 79% to 93% (Figure 4; P = 0.28).Equine bone marrow-derived MSCs secrete soluble factors
that suppress activated PBMCs
In the absence of direct contact between the MSCs and
PBMCs, proliferation of the activated PBMCs was inhib-
ited to a significantly lesser degree than that observed
when cells were in direct contact (94% inhibition with
direct contact; 55% inhibition in transwell system; P =
0.006; Figure 5A).
Furthermore, conditioned media taken from cultures
of actively proliferating MSCs cultured under standard
conditions was used in the PBMC proliferation assays.
Media that had been conditioned for 72 hours was
found to bring about a 56% inhibition of proliferation,
which was not significantly different from that seen in
Figure 2 Proliferation of equine PBMCs is suppressed by co-culture with equine MSCs. (A) Immunocytochemical staining of IFN-γ-treated
mesenchymal stem cells (MSCs) for MHC I and MHC II. Cell nuclei are indicated by blue Dapi staining, and expressed MHC I or II proteins, by
green staining. Data show representative images from one of three replicates. (B) Relative proliferation of effector (Eff#1) peripheral blood
mononuclear cells (PBMCs) to mesenchymal stem cells (MSCs) cultured in the presence and absence of IFN-γ. Autologous and allogeneic stimulator
cells are used as negative and positive controls (Stim #1 and Stim #2, respectively). *Results significantly different from those for nonactivated (NA)
PBMCs (P < 0.05). Error bars represent the standard error of six individual experimental repeats by using three different cell lines.
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strates that the MSCs release soluble factors, even in the
absence of any signals received from the PBMCs.
The factors released by equine MSCs also cause changes
in the cytokine-expression profile and protein production
of activated PBMCs
sAg-stimulation of PBMCs resulted in an increase in ex-
pression of IL-6, TNF-α, and IFN-γ mRNA (Figure 6).
The presence of 24– to 72-hour MSC-conditioned media
significantly reduced this upregulation in IL-6, and IFN-γ
mRNA (P < 0.01 for each time point). Addition of 48- and
72-hour MSC-conditioned media reduced expression of
IL-6 mRNA to a level not significantly different from that
of unstimulated PBMCs. The observed reduction in ex-
pression of TNF-α mRNA did not reach significance for
24-, 48-, or 72-hour conditioned media (P = 0.09, 0.08,
0.07, respectively). No significant changes in gene expres-
sion were observed for the chemokines IP-10, IL-8, andCCL5 after activation of PBMCs by sAgs, and incubation
with MSC-conditioned media had no additional effect
(Figure 6).
MSC-conditioned media contained very low concentra-
tions of the proteins IFN-γ, TNF-α, and IL-10 (Figure 7).
Media from nonstimulated PBMCs also contained very
low concentrations. Production of IL-10 by PBMCs
was significantly increased in response to both MSC-
conditioned media and sAg stimulation, when compared
with nonstimulated PBMCs (P < 0.05). Concentrations of
IFN-γ and TNF-α in the media of sAg-stimulated PBMCs
were significantly higher than those in nonstimulated
PBMCs (P < 0.05). Culture in MSC-conditioned media sig-
nificantly reduced this increase for IFN-γ, although con-
centrations remained significantly higher than those found
in nonstimulated controls (P < 0.05). Culture in MSC-
conditioned media reduced TNF-α concentrations, al-
though this reduction was significant for only 48-hour
conditioned media (P = 0.04) and not for 72-hour condi-
tioned media (P = 0.06) (Figure 7).
Figure 3 Proliferation of peripheral blood mononuclear cells (PBMCs) is increased with either S. equi super-antigens (sAg) or
phytohemagglutinin (PHA) compared with nonactivated (NA) PBMCs and is inhibited by co-culture with allogeneic mesenchymal stem
cells (MSCs). Graph depicts radioactive thymidine (3H-thymidine) counts per minute (cpm) as a measure of cell proliferation. Error bars represent
the standard deviation of triplicate wells of the same experiment, which is representative of the three replicates.
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erate concentrations of IL-6 protein, significantly more
than nonstimulated PBMCs, in which expression was
very low (P < 0.05). Stimulation of PBMCs with sAgs in-
creased IL-6 production, but this failed to reach signifi-
cance (P = 0.08). Culture of PBMCs in MSC-conditioned
media resulted in concentrations of IL-6 that were not
significantly different from those measured in MSC-
conditioned media (Figure 7; P < 0.05).Figure 4 Percentage inhibition of S. equi superantigen (sAg)-induced
co-cultured with mesenchymal stem cells (MSCs) at ratios of 1:10, 1:6
standard error of the mean of three biologic repeats. No significant differenDiscussion
When research into regenerative medicine was in its in-
fancy, it was assumed that the observed clinical benefit
of exogenous MSCs was due to in situ differentiation of
the multipotent cells in a tissue-specific manner. This
simplistic view is gradually being replaced with a more
sophisticated understanding of the paracrine effect of
such cells and their role secreting bioactive molecules
and delivering soluble factors to the host cells. Thisperipheral blood mononuclear cells (PBMCs) proliferation when
6, 1:200, and 1:400 (MSC to PBMC). Error bars represent the
ces are observed between the ratios (P > 0.05).
Figure 5 Soluble factors are involved in MSC-mediated PMBC suppression. (A) Mesenchymal stem cells (MSCs) suppress S. equi
superantigen (sAg)-induced peripheral blood mononuclear cells (PBMCs) proliferation when separated by a transwell membrane (TW). Graph
depicts radioactive thymidine (3H-thymidine) counts per minute (cpm) as a measure of cell proliferation. Differing letter annotations denote a
significantly different mean (ANOVA, all P < 0.05). Error bars represent the standard error of the mean of three biologic repeats. (B) Exposure to
24-, 48-, and 72-hour mesenchymal stem cell (MSC)-conditioned media suppresses S. equi superantigen (sAg)-induced peripheral blood
mononuclear cell (PBMC) proliferation, but to a lesser extent than via direct cell-to-cell contact. TW, transwell. *Results significantly different from
no transwell (No TW) values (ANOVA; P < 0.05). Error bars represent the standard error of the mean of three biologic repeats.
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erties of MSCs and ESCs and contributes supporting evi-
dence for the future clinical application of allogeneic cells
as a regenerative therapy.
The International Society for Cellular Therapy (ISCT)
defined human MSCs as being MHC I positive and MHC
II negative [40], and previous reports confirmed that
equine MSCs express MHC I [28,31,34,41,42]. MHC I
expression has been reported in 62% to 99% of equine
MSCs in these reports, with variability probably due to
differences in cell source, passage, antibodies, and la-
boratory techniques. Multiple studies have shown that
equine MSCs do not express MHC II [28,31,34,41];
however, a more recent article suggests that equine
MSCs may express variable levels of MHC II, depending
on the passage, horse, cell isolation repeat, or culture
conditions [42]. Here we demonstrate that both equineESCs and MSCs, under our culture conditions, express
MHC I but not MHC II.
In other species, it is well established that allogeneic
MHC-mismatched MSCs do not elicit a proliferative re-
sponse when cultured with allogeneic PBMCs in vitro,
resulting instead in a significant reduction in proliferative
action [43]. Similar results have recently been demon-
strated in the horse [28] in a T-cell-selective population.
However, contrary to our findings, background suppres-
sion of PBMC proliferation by MSCs was not reported
there; we observed significant baseline suppression of
PBMC proliferation in culture with MSCs, but not with
ESCs. The observed 80% reduction in baseline prolifera-
tion is comparable to that observed in canine studies [44].
Our study further supports this concept of immune
modulation, with MSCs implementing a reduction in
alloreactive lymphocyte proliferation independent of cell
Figure 6 mRNA expression by nonactivated (NA) and S. equi superantigens (sAg)-stimulated peripheral blood mononuclear cells
(PBMCs) after exposure to 24-, 48-, and 72-hour MSC conditioned media (that is, NA24 represents nonactivated PBMCs exposed to
24-hour MSC-conditioned media). Results represented as change in fold expression relative to NA PBMCs (control conditions), adjusted to the
housekeeping gene 18S. Error bars represent the standard error of the mean from three individual experiments using three cell lines. *Results significantly
different (P< 0.05) from those for NA PBMCs, ¥ denotes values significantly different (P< 0.05) from sAg-stimulated PBMCs (sAg, stimulated control).
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contrast to a previous report in the horse [28] and may
reflect differences in the immune cell population (T-cell-
selective versus nonenriched PBMC population) or dif-
ferences in the actual numbers of MSCs used, which has
been shown to affect their suppressive effects [45]. We
further demonstrated, for the first time in the horse, that
MSC-mediated suppression of PBMC proliferation also
occurs when using indirect culture or MSC-conditioned
media. This supports recent data that demonstrate the
involvement of secreted prostaglandin E2 in MSC-mediated
T-cell suppression [29].
Human adipose-derived multipotent stem cells (AdMSs)
demonstrated similar immunomodulatory effects to BMSCs,
with both sources suppressing proliferation of stimulated
PBMCs and inhibiting monocyte-derived immature den-
dritic cell differentiation. However, the AdMS cells ap-
peared more potent and secreted greater concentrationsof IL-6 and TGF-β1, suggesting that the increased cyto-
kine secretion may contribute to a greater immunomodu-
latory potency [46]. The proposal that cytokine secretion
forms at least part of the mechanism of action is sup-
ported in our study by the demonstration that direct con-
tact between cell types is not necessary for the observed
inhibitory effect; indeed, simultaneous presence of both
MSCs and PBMCs was shown to be not essential, as
MSCs are able to suppress alloreactive lymphocytes in
both indirect (transwell) and time-lapsed (preconditioning)
culture.
Both mRNA and protein expression for the proinflam-
matory cytokines TNF-α and IFN-γ by activated PBMCs
was reduced by culture in MSC-conditioned media. This
finding supports previously reported decreases in TNF-α
and IFN-γ mRNA expression in human, murine, and
equine studies [27,28,47,48], and supports the hypothesis
that MSCs promote tissue healing via their ability to
Figure 7 Concentration of cytokines produced by nonactivated (NA) and S. equi superantigen (sAg)-stimulated peripheral blood
mononuclear cells (PBMCs) after exposure to 24-, 48-, and 72-hour MSC-conditioned media, measured with ELISA (that is, NA24
represents nonactivated PBMCs exposed to 24-hour MSC-conditioned media). Error bars represent the standard error of the mean from
three individual experiments using three cell lines. *Results significantly different from those for nonactivated PBMCs (NA), ¥, Values significantly
different (P < 0.05) from sAg-stimulated PBMCs (sAg).
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expression of IL-6 mRNA was similarly decreased in the
presence of MSC-conditioned media, the higher base-
line production of IL-6 by MSCs may have masked any
corresponding downregulation in protein expression by
PBMCs. Our finding that equine MSCs constitutively
express IL-6 is in contrast to previous reports [28], al-
though in agreement with findings from other species
[49]. It has been suggested that IL-6 production by
MSCs is a key component of their immune privilege and
that postimplantation rejection of allogeneic MSCs may
be related to a reduction in cellular IL-6 concentrations
[49], although inhibition of IL-6 did not affect equine
MSC-mediated T-cell suppression in a recent study [29].
Our study found no increase in chemokine mRNA
expression (IP-10, CCL5, IL-8) after sAg activation of
PBMCs. In contrast, studies on human allogeneic
MSCs and PBMCs demonstrated upregulation of chemo-
kine expression and protein release after stimulation with
inflammatory mediators [50]. It is also hypothesized that
MSCs promote antiinflammatory signaling, by upregu-
lating key antiinflammatory cytokines such as IL-10
[27,28,30], as observed here.
We, and others previously demonstrated that MSCs
upregulate MHCI expression and induce expression of
MHCII in response to IFN-γ [34,42]. Although our study
did not quantify the level of expression, this would beinteresting to explore in future experiments, as our re-
sults suggest that although the majority of equine MSCs
and ESCs express MHC I under normal conditions, the
level of expression is increased after IFN-γ treatment. In
addition, IFN-γ acts as a major regulator of the expres-
sion of chemokines and their receptors in human MSCs
[50]. Although in human tendons, IFN-γ levels remain
below detection levels after injury [51], in the injured
equine superficial digital flexor tendon, a significant per-
centage of tenocytes have been shown to be IFN-γ
immunopositive [52]. These data confirm that addition
of IFN-γ does not reduce the immune privilege of either
ESCs or MSCs, although the resultant effect on MHC
expression differed (significant upregulation of MHC I,
with no effect on MHC II in ESC lines, in comparison
with upregulation of both MHC I and II in MSCs).
It has been suggested that low MHC expression results
in a reduction of stimulatory signals to aid in evasion of
an immune attack [22,24], forming an additional or alter-
nate mechanism by which MSCs and ESCs were able to
avoid stimulation of a proliferative response in PBMCs.
Similar findings are attributed to studies on human MSCs
[45,53], but MHC II expression has been associated with
MHC-mismatched T-cell proliferation in horses [42]. The
haplotypes of the horses used in the current study are un-
known, but these conflicting results warrant further re-
search. An absence of co-stimulatory molecules in human
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[54], and although some of these molecules are expressed
at the mRNA level in equine MSCs [41], a lack of equine-
specific antibodies has precluded detailed investigations to
date.
Equine ESCs have been observed to undergo a degree
of tenocyte differentiation after implantation into injured
tendon in vivo and furthermore, not to elicit an immune
response [19]. However, the relative importance of the
host tendon tissue in this immune privilege is not known,
as equine ESCs have not, to date, been implanted into
other tissues. In this study, we demonstrated that equine
ESCs do not induce the proliferation of allogeneic PBMCs,
even after their spontaneous differentiation. This may in
part be due to a lack of MHC II expression by both undif-
ferentiated and differentiated ESCs, even after exposure to
IFN-γ and supports results reported in ESCs from other
species [24]. When equine ESCs are allowed to undergo
spontaneous differentiation, a mixed population of differ-
entiated cell types is produced, which contains cells de-
rived from all three germ layers [17,18]. The observed lack
of induction of PBMC proliferation after in vitro differen-
tiation therefore supports further in vivo research into
their application in other tissues. Unlike, MSCs, equine
ESCs did not suppress baseline PBMC proliferation, which
may suggest that they do not have the same immunosup-
pressive properties as MSCs. However, the effect of ESCs
on the proliferation of activated PBMCs was not per-
formed in this study and should be addressed in the
future.
Furthermore, the effect of repeated doses of stem cells
for therapeutic aims is not known and should form part
of future work. In baboons, multiple administrations of
high doses of allogeneic MSCs reportedly affected allor-
eactive immune responses without compromising the
overall immune system of recipient baboons [55]. The
authors concluded that induction of host T-cell hypore-
sponsiveness to donor alloantigens may facilitate MSC
survival. Additionally, equine umbilical cord blood stem
cells neither stimulated, nor suppressed, baseline prolifera-
tion rates of PBMCs in vitro, or after repeated administra-
tion in vivo [30].
Conclusion
In conclusion, both MSCs and ESCs are attractive tar-
gets for the development of allogeneic cellular therapy.
Equine ESCs did not affect baseline PBMC proliferation,
even after differentiation and/or MHC upregulation by
IFN-γ. In contrast, equine MSCs have a profound sup-
pressive effect on allogeneic lymphocytes, a feature not
dependent on MHC expression, suggesting efficacy re-
gardless of donor MHC haplotype. Preservation of this
suppressive effect on mitogen-stimulated PBMCs, along with
the suppression of pro-inflammatory cytokine production,suggests that clinical delivery into an inflamed environment
may also be valuable. MSCs have potential as immune-
regulatory tools for the treatment of immune-mediated
and inflammatory diseases, such as osteoarthritis and in-
flammatory airway disease, through their ability to pro-
duce immunomodulatory trophic factors.
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